ID.1
Item
age 18 or older
boolean
ID.2
Item
men and women locally advanced, metastastic and/or recurrent nsclc with adenocarcinoma histology for which vargatef treatment is indicated according to summary of product characteristics (smpc)
boolean
ID.3
Item
after first line therapy; second-line therapy not yet started
boolean
ID.4
Item
standard 21-day-cycles docetaxel treatment according to smpc possible
boolean
ID.5
Item
written informed consent
boolean
ID.6
Item
contraindications according to the smpc of vargatef or docetaxel
boolean
ID.7
Item
more than one systemic therapy for treatment of nsclc in palliative setting
boolean
ID.8
Item
current partcipation in another non-interventional study or a clinical trial
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
breastfeeding
boolean